Patient has acute promyelocytic leukemia (APML)
Patients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, or bone marrow failure syndromes are not eligible
Newly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia) and has failed one or two prior standard induction attempts. Failure is defined as:
Acute promyelocytic leukemia
Diagnosis of acute promyelocytic leukemia (M3 classification)
Subject has acute promyelocytic leukemia
Participant has acute promyelocytic leukemia
Subjects diagnosed with Acute Promyelocytic Leukemia.
Acute Promyelocytic Leukemia
Patients with a diagnosis of acute promyelocytic leukemia
Acute promyelocytic leukemia with PML-RARA or t(15;17)
Acute promyelocytic leukemia
Patients with acute promyelocytic leukemia
Patients who have received any therapy other than hydroxyurea or ATRA with the purpose of treating their AML or patients with acute promyelocytic leukemia are not eligible
Acute promyelocytic leukemia
Diagnosis of acute promyelocytic leukemia
Has a diagnosis of acute promyelocytic leukemia.
Subjects with acute promyelocytic leukemia (M3)
AML is of the sub-type of acute promyelocytic leukemia
Has acute promyelocytic leukemia (AML subtype M3)
Acute promyelocytic leukemia
Acute promyelocytic leukemia
Acute promyelocytic leukemia
Subject has a diagnosis of acute promyelocytic leukemia
Acute Promyelocytic Leukemia
Patients with acute promyelocytic leukemia
Acute promyelocytic leukemia (FAB M3)
Acute Promyelocytic Leukemia (AML subtype M3).
Subject has acute promyelocytic leukemia.
Unequivocal diagnosis of AML based on the WHO classification, excluding acute promyelocytic leukemia
Acute promyelocytic leukemia (FAB M3 classification)
Acute promyelocytic leukemia
Acute Promyelocytic Leukemia
Diagnosis of acute promyelocytic leukemia
Patients with acute promyelocytic leukemia are excluded
Acute promyelocytic leukemia with t(15;17)(q22;q12) and/or PML-RARA molecular rearrangement
Dose Escalation: Acute Promyelocytic Leukemia
Have acute promyelocytic leukemia and the associated cytogenic translocation t:(15/17)
Diagnosis of AML-M3 (or acute promyelocytic leukemia)
Acute promyelocytic leukemia (AML with t[15;17][q22;q11] and variants)
Diagnosis of acute promyelocytic leukemia
Acute promyelocytic leukemia [t(15;17)]
Patients with acute promyelocytic leukemia
Diagnosis of AML-M3 (or acute promyelocytic leukemia)
Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16 if known at the time of randomization.
The patient must not have acute promyelocytic leukemia or t(15;17) observed by FISH
Acute promyelocytic leukemia
Subjects with a diagnosis of Acute Promyelocytic Leukemia
Promyelocytic leukemia
Patients with a diagnosis of acute promyelocytic leukemia (according to WHO classification 2008)
Subjects with the diagnosis of acute promyelocytic leukemia (t[15;17])
All subtypes of Acute Myeloid leukemia (except for acute promyelocytic leukemia)
Diagnosis of acute promyelocytic leukemia
Patients with acute promyelocytic leukemia according to WHO definition.
Acute promyelocytic leukemia or AML with a t(15;17) (q22;q12) cytogenetic abnormality or Bcr/Abl positive leukemia
Acute promyelocytic leukemia
Acute promyelocytic leukemia with t(15;17), or its molecular equivalent (PML-RARalpha)
Newly Diagnosed De novo AML according to WHO criteria except for Acute Promyelocytic Leukemia or patients with known favorable cytogenetics (see exclusion)
Newly diagnosed patients with Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16
A diagnosis of acute promyelocytic (M3) or acute megakaryocytic leukaemia (M7).
Acute promyelocytic leukemia.
Documented/confirmed acute myelogenous leukemia (AML), except for acute promyelocytic leukemia
Diagnosis of acute promyelocytic leukemia
The patient has acute promyelocytic leukemia with t(15;17) (q22;q12), (PML/RAR?) or variants.
Diagnosis of acute promyelocytic leukemia
The patient has acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RAR?) or variants.
Newly Diagnosed De novo AML according to WHO criteria except for Acute Promyelocytic Leukemia or patients with known favorable cytogenetics
Newly diagnosed patients with Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16
A diagnosis of acute promyelocytic leukemia (APML)
Acute promyelocytic leukemia
Patients with acute promyelocytic leukemia
Patients with acute promyelocytic leukemia
Acute promyelocytic leukemia
Patients with a diagnosis of acute promyelocytic leukemia
AML subtype M3 (promyelocytic leukemia)
Patients must have a documented Unequivocal diagnosis of AML according to WHO 2008 classification (>20% blasts in the bone marrow), excluding M3 (acute promyelocytic leukemia).
Acute promyelocytic leukemia.
Diagnosis of acute promyelocytic leukemia
Acute promyelocytic leukemia (M3 classification).
Acute promyelocytic leukemia
Primary or secondary AML (including erythroleukemia and eosinophilic leukemia, but excluding acute promyelocytic leukemia)
Diagnosis of promyelocytic leukemia
Patients must have high-grade bladder cancer as defined by 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classification
Patients with low grade glioma patients (World Health Organization [WHO] grades I and II) are not eligible
Neuroendocrine tumors (NETs), grade 2 and grade 3 according to World Health Organization classification.
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient must not have Burkittâ€™s lymphoma/leukemia based on the World Health Organization (WHO) criteria
Dose Escalation - Relapsed or refractory AML (excluding acute promyelocytic leukemia) or PDCN, based on World Health Organization Classification. All patients enrolled on this study will have CD123+ disease.
Diagnosis of one of the following histologic subtypes of PTCL, pathologically-confirmed, as defined by the World Health Organization:
Diagnosis of AML per World Health Organization (WHO) criteria (except acute promyelocytic leukemia)
Morphologically confirmed diagnosis of MDS or MDS/MPN in accordance with World Health Organization (WHO) diagnostic criteria
Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) which is relapsed or refractory after failing at least 1 regimen and is not a candidate for established salvage treatment regimens
Documented pathological evidence of MDS as defined by the World Health Organization (WHO) criteria
Have histologically confirmed World Health Organization (WHO) grade II or III meningioma that is progressive or recurrent; metastatic meningiomas are allowed; participants must have failed maximal safe resection and radiation therapy
Single agent (SA) Dose Escalation: Histologically or cytologically proven acute leukemia or high-risk MDS as defined by the World Health Organization (WHO) criteria and IPSS-R, respectively, that is relapsed or refractory (R/R) to standard therapy or for whom standard treatments are contraindicated, OR
World Health Organization (WHO) performance status =< 2
Diagnosis of PTCL according to the most recent edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues, as follows:
Refractory or relapsed lymphoma (per World Health Organization (WHO) Classification system)
Diagnosis of de novo or secondary myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia, as defined by the 2008 World Health Organization classification system
A diagnosis of acute promyelocytic leukemia as defined by the 2008 World Health Organization classification system
Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria with ?20% bone marrow blasts based on histology or flow cytometry
Subject has documented, histologically locally confirmed, previously untreated CD20+ DLBCL (NOS) per World Health Organization (WHO) classifications (Swerdlow, 2008).
A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification that is progressing.
RAEB-1 per World Health Organization (WHO) MDS criteria (5% to <10% BM blasts)
World Health Organization (WHO) performance status equal to 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
Patients must have a histologic diagnosis of meningioma, World Health Organization (WHO) grade 2 or 3 (atypical or anaplastic)
Diagnosis of CMML as defined by the World Health Organization (WHO) criteria.
Histologically confirmed atypical meningioma, World Health Organization (WHO) grade II, Simpson grade 4-5 that has been either subtotally resected or biopsied; OR
RR DLBCL per the 2008 World Health Organization (WHO) classification of hematopoietic and lymphoid tumors (Swerdlow et al, 2008).
Diagnosis of a b-cell malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
World Health Organization (WHO)-confirmed acute myeloid leukemia (AML)
Eastern Cooperative Oncology Group (ECOG) (World Health Organization [WHO]) performance status 0 or 1 or 2
Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma
Histologically confirmed diagnosis of World Health Organization grade IV malignant glioma
World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG)-performance status 0-2
A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification.
Must have pathologically documented, and definitively diagnosed World Health Organization (WHO) grade 4, glioblastoma
World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
Diagnosis of recurrent or progressive histologically confirmed World Health Organization (WHO) grade I-III meningioma which has failed maximal safe resection and radiation therapy
Diagnosis of AML by World Health Organization (WHO) criteria. Patients with high risk myelodysplastic syndrome (MDS) as defined by the presence of >= 10% blasts are also eligible at the discretion of the principal investigator
Patients with a diagnosis BPDCN according to World Health Organization (WHO) classification confirmed by hematopathology;
Patients must have histologically confirmed ND or R/R PTCL defined according to the 2016 World Health Organization (WHO) classification criteria, with no accepted curative options\r\n* Patients with extranodal natural killer (NK)/T-cell lymphoma may only be allocated to treatment Arm D
Participant must have histological confirmation of Acute Myeloid Leukemia (AML) by World Health Organization criteria, be ineligible for intensive induction chemotherapy and either be:
Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria
Diagnosis of MDS as defined by the World Health Organization (WHO) diagnostic criteria
Subjects must have IPSS-R high or very high risk myelodysplastic syndromes (MDS) by World Health Organization (WHO) classification
AML according to world health organization (WHO) criteria (i.e. bone marrow blasts >20%)
Patients with World Health Organization (WHO) class III or IV pulmonary hypertension
Histologically documented diagnosis (based on the 2008 World Health Organization [WHO] Classification) of one of the following:
Pathologically documented, and definitively diagnosed recurrent World Health Organization (WHO) Grade IV astrocytoma (GBM).
Subjects must have histologically or cytologically confirmed World Health Organization (WHO) grade 4 glioma for which a clinically indicated tumor resection is planned
Subjects must have histologically confirmed diagnosis of World Health Organization (WHO) grade III or IV malignant glioma
For Part 1 of the study, participants must have histopathologically confirmed diagnosis of R/R, DLBCL, FL, MZL/MALT, MCL, or other Sponsor approved NHL subtypes according to the World Health Organization (WHO) classification 2008 for which standard measures do not exist or are no longer effective.
Documented/confirmed first/second refractory/relapsed AML using World Health Organization classification, except acute promyelocytic leukemia
World Health Organization (WHO) performance status 0-2
World Health Organization Performance Status of 0 to 1.
Patients must have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic Neoplasms
Diagnosis of 1) AML (World Health Organization [WHO] classification definition of >= 20% blasts), or 2) high risk MDS (defined as the presence of 10% blasts)
History of AML according to World Health Organization (WHO) classification
Histologic confirmation of thymic carcinoma (World Health Organization [WHO] classification)
Mature T-cell non-Hodgkin lymphoma (see World Health Organization [WHO] for specific malignancies)\r\n* First CR\r\n* Relapse after greater than or equal to 1 prior regimen
Must have a histopathologically documented diagnosis of primary or secondary AML (excluding acute promyelocytic leukemia), as defined by World Health Organization (WHO) criteria (Jaffe et al, 2001), for whom no standard therapies are anticipated to result in a durable remission according to the clinical judgment of the principal investigator, or who refuses standard therapies (phase 1b and 2).
World Health Organization (WHO) performance status 0-2
Diagnosis of AML (World Health Organization [WHO] classification definition of >= to 20% blasts)
Diagnosis of myelodysplastic syndrome (MDS) confirmed within 10 weeks prior to study entry according to World Health Organization (WHO) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplant
Performance status (World Health Organization [WHO]/Eastern Cooperative Oncology Group [ECOG] scale) 0-2
Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
Histologically confirmed mantle cell lymphoma classified according to World Health Organization (WHO) criteria confirmed at MSKCC
History of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts ?20%).
World Health Organization (WHO) performance status =< 2
Myelodysplastic syndrome as defined by World Health Organization (WHO) criteria
Histologically confirmed diagnosis of World Health Organization (WHO) I-III meningiomas and hemangiopericytomas
Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRT
Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification
Confirmed diagnosis of AML according to World Health Organization (WHO) 2016 classification
Histologically or cytologically documented diagnosis of MDS according to the World Health Organization (WHO) classification (Vardiman 2009, Arber 2016) with >5% and <20% bone marrow blasts by morphology and a peripheral white blood cell (WBC) count of <20,000/?L
Cytologically or histologically confirmed diagnosis of MDS or CMML according to the 2008 World Health Organization (WHO) classification.
Diagnosis of AML per World Health Organization criteria
The subject must have histological confirmation of GBM (World Health Organization [WHO] grade IV)
Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:
Histologically confirmed diagnosis of World Health Organization grade III or IV malignant glioma
Morphologically confirmed new diagnosis of AML in accordance with World Health Organization (WHO) diagnostic criteria
Newly diagnosed and histologically confirmed supratentorial World Health Organization (WHO) Grade IV astrocytoma status-post maximally achievable resection
Patients must have histologically or cytologically confirmed AML according to the World Health Organization (WHO) criteria
Diagnosis of acute myeloid leukemia (AML) as defined by the World Health Organization
Documented diagnosis of primary myelofibrosis according to World Health Organization (WHO) criteria or post polycythemia vera (PV) myelofibrosis or post essential thrombocythemia (ET) myelofibrosis as per IWG-MRT criteria
A diagnosis of ET or PV shall be made in accordance with the World Health Organization (WHO) (2008) criteria (Swerdlow 2008)
Diagnosis of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as documented by medical records and with histology based on criteria established by The World Health Organization (WHO):
Relapsed or refractory CD25-positive AML [per World Health Organization (WHO)].
Relapsed or refractory CD25-positive ALL [per World Health Organization (WHO)].
Diagnosis of a hematologic malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status 0-1
Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and with histology based on criteria established by the World Health Organization
Age ? 18 years at the time of signing the informed consent form. 8. Central confirmation of diagnosis of previously untreated primary or secondary Myelodysplastic syndromes (MDS) as per World Health Organization (WHO) classification. Results of central pathology review are required prior to receiving the first dose of IP.
World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
Myelodysplastic Syndrome (MDS) according to the World Health Organization (WHO) 2008 classification
World Health Organization (WHO) risk score 0-6
A diagnosis of SM per 2008 World Health Organization (WHO) criteria; patients with ASM and MCL, or SM-AHNMD are required to have at least one of the eligible organ damage findings as defined by the international consensus response criteria (Gotlib, 2013)
A diagnosis of systemic mastocytosis (SM) per 2008 World Health Organization (WHO) Criteria
Subject has a diagnosis of previously-untreated AML according to World Health Organization (WHO) classification [Swerdlow et al, 2008] as determined by pathology review at the treating institution.
In Part 1, diagnosis of myelodysplastic syndrome (MDS) according to World Health Organization (WHO) criteria
World Health Organization (WHO) performance status of 0, 1, or 2
Performance status (World Health Organization [WHO] scale) < 2
World Health Organization (WHO) performance score of 0 to 1 with life expectancy of at least 3 months
World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks
Diagnosis of CLL meeting criteria established in the World Health Organization (WHO) classification of hematologic disorders
JAK2V617F-positive PV or JAK2V617F-positive ET (confirmed by World Health Organization [WHO] diagnostic criteria)
World Health Organization (WHO) Performance Status of 0 or 1
World Health Organization Performance Status of 0 to 1 with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks
Patients with thymic carcinoma (formerly World Health Organization [WHO] type C)
World Health Organization (WHO) performance status 0-1
World Health Organisation (WHO) Performance Status of 0 to 1.
World Health Organisation (WHO) Performance Status of 0 or 1
Diagnosis of acute myelogenous leukemia (AML) according to World Health Organization (WHO) criteria;
Diagnosis of histologically confirmed GBM (World Health Organization [WHO] grade IV)
Patients must have a diagnosis of CLL/SLL or B-cell prolymphocytic leukemia, as defined by the World Health Organization (WHO)
Age >= 70, or age >= 60 ineligible for treatment with standard induction chemotherapy (based on physician discretion or patient refusal), with a new diagnosis of AML based on World Health Organization classification
World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
Confirmed diagnosis of CMML using the World Health Organization (WHO) classification
primary myelofibrosis (PMF) per the revised World Health Organization (WHO) criteria
Subject must have histologically documented diagnosis of non-Hodgkin's lymphoma as defined by a B-cell neoplasm in the World Health Organization classification scheme except as noted in exclusion criteria.
Patients must have a World Health Organization performance status =< 2
Patients with World Health Organization performance status of 3 or 4
Must have measurable disease by modified World Health Organization (WHO) criteria
Diagnosis of essential thrombocythemia according to revised World Health Organization (WHO) 2016 criteria.
World Health Organization (WHO) performance status 0-2
Subjects with cytologically/histologically confirmed MDS according to the World Health Organization (WHO) 2008 classification.
Patients with a new diagnosis of histologically confirmed (according to World Health Organization [WHO] classification 2008) acute myeloid leukemia (either primary or secondary AML) are included
Patients must have a previous morphologically confirmed diagnosis of AML based on World Health Organization (WHO) criteria
Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
World Health Organization (WHO) Performance Status (PS) ? 2
Frozen section diagnosis of World Health Organization (WHO) grade IV glioma, confirmed with permanent section and immunopositive for IGF-1R
A diagnosis of acute myeloid leukemia (AML) based on World Health Organization (WHO) classification (>= 20% myeloblasts in peripheral blood or bone marrow)
Patients must have a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL) of non-GCB subtype, established according to the World Health Organization (WHO) criteria that has been tested for the MyD88 L265P mutation.
Eastern Cooperative Oncology Group (World Health Organization) performance status of 0 or 1
Newly-diagnosed AML by World Health Organization (WHO) criteria (>= 20% myeloid blasts by morphology in either blood or marrow)
Subject is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:
Biopsy-proven diagnosis of cHL (regardless of Hodgkin/Reed-Stemberg [HRS] cell cluster of differentiation [CD]20 expression) per the World Health Organization classification criteria; lymphocyte predominant histology is excluded
The patient has a diagnosis of AML according to World Health Organization (WHO) criteria.
Have histologically or cytologically confirmed recurrent Grade 2 or 3 LGG (oligodendroglioma or astrocytoma according to World Health Organization 2016 classification).
Diagnosis of histopathologically confirmed B-cell NHL (as per the World Health Organization [WHO] 2016 classification) including WM/LPL.
Documentation that the participant has met the revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia vera (PV)
Indolent NHL subtypes defined according to World Health Organization guidelines:
Pre-study World Health Organization (WHO) performance status of 0, 1, or 2
The patient has cytologically proven AML as defined by the World Health Organization (WHO) classification. The pretreatment AML karyotype should be documented.
Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status 0-2
Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor
Patients must have histologically confirmed World Health Organization (WHO) grade 2 or 3 gliomas
Diagnosis of B cell non-Hodgkin lymphoma confirmed by World Health Organization (WHO) criteria
Patients with newly diagnosed World Health Organization (WHO) grade III or IV astrocytoma who will undergo concomitant radiation and temozolomide followed by adjuvant temozolomide
Receiving health care primarily through an health maintenance organization (HMO)
Attained menopause as defined by World Health Organization Criteria
Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0-2
Patient has Karnofsky score >= 50 or World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) =< 2 if >= 16 years of age
Patients must have a World Health Organization performance status of =< 2
Score of >= 8 on the World Health Organization (WHO) Alcohol Use Disorders Identification Test (AUDIT, sensitivity of 0.8)
Tumor pathology: suspected or confirmed newly diagnosed or recurrent malignant gliomas World Health Organization (WHO) grade IV
Karnofsky performance status of ? 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status (KPS) ? 50 (Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] 0, 1, or 2)
Karnofsky performance status (KPS) ? 50 (Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] 0, 1, or 2)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of 50 or greater (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/ World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status or Lansky play scale status of >= 60 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis per World Health Organization 2008 criteria
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status or Lansky Play Scale status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status or Lansky Play Scale status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO 2000] classification).
Patients with secondary APL are excluded; this includes all patients with APL that may have resulted from prior treatment (chemotherapy or radiation)
Must not have received systemic antineoplastic therapy including radiation therapy within 14 days of the study enrollment, except hydroxyurea or 6-mercaptopurine for the purposes of cytoreduction; patients may also have received all-trans retinoic acid (ATRA) if there is an early suspicion of acute promyelocytic leukemia (acute promyelocytic leukemia [APL], M3-AML), although if confirmed to have APL these patients will be excluded from the study
Subject has a diagnosis of acute promyelocytic leukemia (APL)
COHORT 1: Have histologically or cytologically confirmed relapsed or refractory AML (i.e. >= 5 % blasts by manual differential on bone marrow aspirate / biopsy / flow cytometry), excluding acute promyelocytic leukemia (APL; FAB M3; t [15; 17])
COHORT 2: Have histologically and cytologically confirmed newly diagnosed AML (i.e. >= 20% blasts by manual differential on bone marrow aspirate/biopsy and/or in peripheral blood), excluding acute promyelocytic leukemia (APL; FAB M3, t [15;17])
Documented AML by peripheral blood or bone marrow analyses meeting World Health Organization (WHO) criteria, excluding patients with acute promyelocytic leukemia (APL)
Subject is diagnosed as acute promyelocytic leukemia (APL).
Acute progranulocytic leukemia (APL, M3)
Diagnosed with acute promyelocytic leukemia (APL, M3)
Subject must have confirmation of non-acute promyelocytic leukemia (APL) AML by World Health Organization (WHO) criteria and be ineligible or unwilling to undergo treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidities or other factors
an established, confirmed diagnosis of AML by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3; and
Patient with AML according to 2016 WHO criteria (excluding acute promyelocytic leukemia [APL] [AML-M3])
Acute promyelocytic leukemia (APL).
World Health Organization (WHO)-confirmed AML, other than acute promyelocytic leukemia (APL), with no standard treatment options available
Has a diagnosis of acute promyelocytic leukemia (APL) as defined by the World Health Organization
Acute promyelocytic leukemia (APL); patients with brief exposure to all-trans retinoic acid (ATRA), arsenic trioxide (ATO) or similar product for suspected APL, who later turn out not to have APL, are eligible for the study
Diagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.
Participants that have acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL, M3 subtype of AML) or patients with a t(9:22) cytogenetic translocation.
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically documented newly diagnosed de novo acute myeloid leukemia (non-acute promyelocytic leukemia [APL]) that has not yet been treated; hydrea and all-trans retinoic acid (ATRA) previous treatments are acceptable
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARA
Patients must have histologically confirmed AML or ALL, excluding acute promyelocytic leukemia (APL); for histological confirmation, a bone marrow biopsy and aspirate must be reviewed at Oregon Health & Science University (OHSU)
Diagnosis acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA)
Has a diagnosis of acute promyelocytic leukemia (APL) as defined by the World Health Organization
Acute promyelocytic leukemia (APL, M3) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantation
APL (acute promyelocytic leukemia) by WHO criteria [AML with t(15;17)]
Subjects with acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M3) with a bone marrow of >5% blasts based on histology or flow cytometry
Diagnosed with acute promyelocytic leukemia (APL, M3)
AML (acute promyelocytic leukemia [APL] excepted) or high-risk MDS (10-19% blasts in marrow by morphology or flow cytometry or blood)
Has acute promyelocytic leukemia (APL, FAB M3).
Diagnosis of acute promyelocytic leukemia (APL, or AML M3 subtype).
Diagnosis of acute myeloid leukemia (AML) by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3.
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically documented newly diagnosed acute myeloid leukemia (non-acute promyelocytic leukemia [APL]) that has not yet been treated; hydroxyurea (Hydrea) and tretinoin (ATRA) previous treatments are acceptable
Patients with acute promyelocytic leukemia (APL) are not eligible
Acute promyelocytic leukemia (APL)
Patients with acute promyelocytic leukemia (APL) confirmed either by the presence of t(15;17)(q22;q21) or promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha transcripts will be excluded
Patients with acute promyelocytic leukemia (APL) as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or FISH or molecular testing
Patients with newly diagnosed or relapsed/refractory AML, except acute promyelocytic leukemia (APL), requiring intensive induction chemotherapy
AML, other than acute promyelocytic leukemia (APL), in first or second remission or with minimal residual disease
Subject was diagnosed as acute promyelocytic leukemia (APL).
The patient has a diagnosis of AML or BPDCN according to WHO classification (AML; excluding acute promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN)
The patient has a diagnosis of AML or BPDCN according to WHO classification (AML; excluding acute promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN)
The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB M3).
Diagnosis of acute promyelocytic leukemia (APL)
AML M3 Acute Promyelocytic Leukemia (APL) or patients with a t(9:22) cytogenetic translocation.
Acute promyelocytic leukemia (APL)
Subject was diagnosed as acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL, M3) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantation
Treatment-related AML or acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
Diagnosis of acute promyelocytic leukemia (APL)
Cytologically/histologically confirmed acute myeloid leukaemia (AML) according to WHO classification; (except for acute promyelocytic leukaemia (APL).
Patient has acute promyelocytic leukemia (APL).
Confirmed diagnosis of non-acute promyelocytic leukemia (APL) AML (World Health Organization [WHO] criteria)
Acute promyelocytic leukemia (APL)
Newly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL))
New diagnosis of AML, other than acute promyelocytic leukemia (APL) or poor-risk AML
Acute promyelocytic leukemia (APL, M3)
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically confirmed nonâ€“acute promyelocytic leukemia (APL) acute myeloid leukemia (AML)
Diagnosis of acute promyelocytic leukemia (APL)
Patients with acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
A diagnosis of acute promyelocytic leukemia (APL); the study does not require to rule APL out for every subject; however, if there is clinical suspicion for APL, such diagnosis has to be ruled out before initiation of treatment
Subject was diagnosed as acute promyelocytic leukemia (APL).
World Health Organization (WHO)-confirmed AML, other than acute promyelocytic leukemia (APL)
Diagnosis of acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL)
Patients with the following diagnoses are not eligible:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Juvenile myelomonocytic leukemia (JMML)
Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); subjects who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).
Acute promyelocytic leukemia (APL) with PML-RARA
Patients must not have acute promyelocytic leukemia (APL) and must not have evidence of t(15;17)(q22;q21)
Patients with newly diagnosed AML or acute promyelocytic leukemia (APL)
Diagnosis of MDS or AML other than APL with t(15;17)(q22;q12), (promyelocytic leukemia[PML]/retinoic acid receptor [RAR]), or variants according to the 2008 World Health Organization (WHO) classification
Subjects with acute promyelocytic leukemia (APL)
Patients with promyelocytic leukemia (French-American-British [FAB] M3)
Patients with MDS must have been diagnosed as MDS by WHO (4th edition) or French-American-British (FAB) classification
RAEB-t per French-American-British (FAB) classification (20% to 30% BM blasts)
Acute promyelocytic leukemia (APL, French-American-British (FAB) subtype M3), according to WHO classification.
Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)
Confirmed diagnosis of MDS according to the French-American-British (FAB) criteria. Subjects with MDS must have intermediate, high, or very high risk IPSS-R scores and cytopenia of at least one lineage.
Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)
Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML, excluding acute promyelocytic leukaemia (APL, French-American British M3 classification):
Acute promyelocytic leukemia (M3 leukemia, per French-American-British classification)
Subjects with French American British (FAB) M3 (t (15; 17) (q22; q21) [promyelocytic leukemia (PML)-retinoic acid receptor (RAR) alpha]) are not eligible
Histologically confirmed diagnosis of a myelodysplastic syndrome, meeting criteria for any subtype in the French-American-British (FAB) or World Health Organization (WHO) classification systems with any International Prognostic Scoring System (IPSS) score
Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by French American British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies
Acute promyelocytic leukemia (French-American-British [FAB] M3 AML)
Diagnosis of acute promyelocytic leukemia (APL, French-American-British [FAB] classification M3 or WHO classification of APL with t (15;17)(q22;q12), promyelocytic leukemia protein [PML]/retinoic acid receptor alpha [RARa] and variants)
AML, any French- American- British (FAB) subtype except M3, with confirmed mutation in the NPM1 gene
Patients with acute promyelocytic leukemia (French-American-British [FAB] class M3 AML)
Diagnosis of MDS according to World Health Organization (WHO) criteria or French-American-British (FAB) classification that must be confirmed by bone marrow (BM) aspirate and/or biopsy within 6 weeks prior to Screening.
Patients with acute promyelocytic leukemia confirmed with t(15;17) (French-American-British Classification [FAB] subtype M3 and M3 variant)
Subjects with untreated AML, if not candidates for standard induction chemotherapy or with poor risk AML (i.e. preceding myelodysplastic syndromes [MDS], myeloproliferative syndromes, leukemia due to cytotoxic chemotherapy for another condition, adverse cytogenetics or complex karyotype), acute promyelocytic leukemia (French-American-British [FAB] M3) is excluded
Subject has French-American-British classification (FAB) type M3 leukemia (acute promyelocytic leukemia) or identification of t(15;17).
Suspected or proven acute promyelocytic leukemia (French-American-British (FAB) M3) based on morphology, immunophenotype, molecular assay, or karyotype; AML associated with t(9;22) karyotype, biphenotypic acute leukemia or AML with previous hematologic disorder such as chronic myelogenous leukemia or myeloproliferative neoplasms.
AML French-American-British (FAB) M3 in first complete remission (CR1)
Patients must have morphologically confirmed newly diagnosed acute myelogenous leukemia (AML) with blood or bone marrow disease; patients with only extramedullary disease in the absence of bone marrow or blood involvement are eligible; note: this protocol uses World Health Organization (WHO) diagnostic criteria for AML; patients with acute promyelocytic leukemia (APL, French-American-British Classification [FAB], M3) or blastic transformation of chronic myelogenous leukemia (CML) are not eligible
Morphologically confirmed diagnosis of MDS or nonproliferative CMML (that is, with white blood cells [WBC] <20,000 per microliter [/mcL]) or low blast AML based on 1 of the following: French American British (FAB) Classifications:
Subjects must have relapsed/refractory AML by world health organization (WHO) classification for which no standard therapies are available or anticipated to result in a durable remission. French- American- British system (FAB) subtype M3 will be excluded.
Participant has acute promyelocytic leukemia (French-American-British Class M3 AML).
Patients with acute promyelocytic leukemia (French-American-British Cooperative group [FAB] M3)
Subjects with acute promyelocytic leukemia (APL) - French-American-British Cooperative group (FAB) M3 (t(15;17)(q22;q21)[promyelocytic leukemia (PML)-retinoic acid receptor (RAR)]) are not eligible
Acute promyelocytic leukaemia (French-American-British (FAB) classification subtype M3).
Acute promyelocytic leukemia (French-American-British [FAB] M3 AML)
Diagnosis of myelodysplastic syndrome (MDS) confirmed within 10 weeks prior to study entry according to World Health Organization (WHO) or French-American-British (FAB) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplant
Confirmed diagnosis of MDS using the World Health Organization (WHO) classification or a diagnosis of WHO myelodysplastic/ myeloproliferative neoplasm (MDS/MPN) or MDS refractory anemia with excess blast in transformation (RAEB-t) by French American British (FAB) classification (acute myeloid leukemia [AML] with 20-30% myeloblasts by WHO classification)
Patients with known acute promyelocytic leukemia (French-American-British class M3-AML)
Acute promyelocytic leukemia (French-American-British Class M3 AML).
Diagnosis of acute promyelocytic leukemia (APL, French-American-British [FAB] classification M3 or World Health Organization [WHO] classification of APL with t[15;17][q22;q12]), (progressive multifocal leukoencephalopathy [PML]/retinoic acid receptor alpha [RARa] and variants)
MDS by World Health Organization (WHO) or French-American-British (FAB) classification
have diagnosis of AML French-American-British (FAB) classification (FAB) M3 (acute promyelocytic leukemia (APL))
Confirmed MDS by bone marrow biopsy according to World Health Organization (WHO) or French-American-British (FAB) criteria
All categories of AML will be included except for acute promyelocytic leukemia (APL) (AML-M3 as defined by 1976 French-American-British [FAB] classification, or APL with t(15;17)(q22;q12); PML-RARA as defined by the revised 2008 World Health Organization [WHO] classification of myeloid neoplasms and acute leukemias), acute megakaryocytic leukemia (AML-M7 type as per FAB or AML [megakaryoblastic] with t(1;22)(p13;q13); RBM15-MKL1 as per WHO 2008 revised classification) and acute leukemias of ambiguous lineage (as per WHO 2008 revised classification), undergoing 7 + 3 remission IC with cytarabine and an anthracycline (daunorubicin or idarubicin); all cases have to be histopathologically confirmed by a diagnostic bone marrow biopsy; use of granulocyte colony-stimulating factor (G-CSF) for any indication must have been discontinued at least 7 days prior to entry into the study
Documented diagnosis of MDS (MYELODYSPLASTIC SYNDROMES), classified according to FAB (FRENCH-AMERICAN BRITISH) classification criteria
Acute myelogenous leukemia (AML (ACUTE MYELOID LEUKEMIA) - FAB (FRENCH-AMERICAN-BRITISH) classification: ? 30% blasts in bone marrow). Subjects known to have ? 30% blasts are not eligible for inclusion in this study. Recognizing limitations of blast cell quantification, this protocol will allow subjects with pre-enrollment (screening/baseline) bone marrow blast counts up to 33% to be considered for inclusion.
